Promethera is currently focused on advancing cell-based medicines using its HepaStem platform into clinical trials in two disease areas, Acute-on Chronic Liver Failure (ACLF) and Nonalcoholic steatohepatitis (NASH). Both indications could benefit greatly from the combined immuno-modulatory and anti-fibrotic properties of HepaStem-derived cell lines.
For all its activities, Promethera is taking a global view early on to pursue a development strategy that maximizes the probability of success. Asia and in particular Japan have taken a cell therapy-friendly position years ago and represent markets of special opportunities. Promethera has benefitted from this trend in Asia already and was able to attract a significant set of both strategic and institutional investors from Japan and South Korea. The Company is committed to exploit these strong initial ties and continue expanding its network into the wider Asian region beyond Japan and South Korea.
As a group, Promethera has assembled a unique set of technological platforms supported by a broad intellectual property portfolio and an experienced international team under one roof. With the acquisition of Cytonet in 2016, the Company has added complementary liver sourcing and manufacturing capabilities for the development of its innovative cell therapies to treat chronic and acquired liver diseases.
In April 2018, Promethera announced the acquisition of Swiss biopharmaceutical company Baliopharm. The transaction complemented Promethera’s pipeline with an innovative antibody-based drug candidate that specifically binds to the tumor necrosis factor receptor 1 (TNF-R1). With the TNF-alpha pathway being implicated in the progression of many inflammatory diseases, including chronic liver diseases leading to fibrosis, a therapeutic antibody approach is a valuable strategy in its own right as well as in combination with Promethera’s cell-based medicines such as the HepaStem technology. The program is currently in preclinical development.
Promethera is committed to further strengthen its research and development capabilities both through internal development activities as well as through partnerships and potentially through strategic transactions.